Studies on the anti-diabetic and hypolipidemic potentials of mangiferin (Xanthone Glucoside) in streptozotocin-induced Type 1 and Type 2 diabetic model rats.
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Context: Mangifera indica (Anacardiaceae) stem bark contains a rich content of mangiferin and is used traditionally in Indian Ayurvedic system to treat diabetes. Purpose of the study: To investigate anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats models. Streptozotocin was used to induce type 1 and type 2 diabetic rats. Mangiferin (at a dose 10 and 20mg/kg) was administrated intra-peritoneally in type 1 and type 2 diabetic rats daily up to 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were estimated. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin were performed and IC50 values were determined. Results: Mangiferin exhibited significant (P<0.05) anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in type 2 diabetic model rats. In addition, mangiferin showed appreciable alpha amylase inhibitory effect (IC50 value 74.35±1.9µg/ml) and alpha glucosidase inhibitory effect (IC50 41.88±3.9µg/ml) when compared with standard drug acarbose (IC50 83.33±1.2µg/ml). Conclusions: Mangiferin showed anti-diabetic as well as hypolipidemic potentials in type 2 diabetic model rats. Therefore, mangiferin possess beneficial effects in the management of type 2 diabetes with hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Medicinal plants of India with anti-diabetic potential
Grover, J. K., Yadav, S., & Vats, V. (2002) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(02)00059-4 · Cited by 1,798
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats
Muruganandan, S., Srinivasan, K., Gupta, S., Gupta, P. K., & Lal, J. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.12.010 · Cited by 426
Cited by
Morozkina, S. N., Nhung Vu, T. H., Generalova, Y. E., Snetkov, P. P., & Uspenskaya, M. V. (2021) · Biomolecules · doi:10.3390/biom11010079 · Cited by 82
“Drug molecules that are able to treat disease, thanks to the ability to be toxic to damaged cells, are usually toxic to healthy cells but mangiferin has a different nature, it is toxic only to diseased cells without damaging normal cells as well as not having an accumulative effect on the liver or kidneys, on the cont…”
BackgroundDethe, S., Gururaja, G., Mundkinajeddu, D., Kumar, A., Allan, J., & Agarwal, A. (2017) · Pharmacognosy Research · doi:10.4103/0974-8490.199770 · Cited by 39
Wang, Y., Karmakar, T., Ghosh, N., Basak, S., & Gopal Sahoo, N. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2021.131376 · Cited by 35
Cholesterol esterase inhibitory activity of bioactives from leaves of Mangifera indica L
Gururaja, G., Mundkinajeddu, D., Dethe, S., Sangli, G., Abhilash, K., & Agarwal, A. (2015) · Pharmacognosy Research · doi:10.4103/0974-8490.159578 · Cited by 34
“indica have studied for many pharmacological activities like anti-diabetic, rheumatid arthritis, anti-inflammatory, hypolipidemic, antioxidant activities.[8-12] Flavonoid rich fraction of kernels of M.”
Background
Metadata
- Authors
- B, D., Mitra, A., & Manjunatha, M.
- Venue
- International Journal of Advances in Pharmaceutical Sciences
- Publisher
- Advanced Research Journals
- Published
- 2010-03-12
- Volume
- 1
- Issue
- 1
- Pages
- 75-85
- ISSN
- 0976-1055 (ISSN-L)
- OpenAlex
- W2088281471
- Cited by
- 83
- References
- 3
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.